TriNetX will provide Regeneron exclusive, secure, licensed access to de-identified real-world health data covering about 300 million individuals, with TriNetX linking genomic and proteomic information for drug discovery and development. The companies position the agreement as a way to accelerate target validation and translational evidence building. The deal focuses on cohorts that can support hypothesis testing across therapy areas, with TriNetX supplying the database infrastructure and Regeneron bringing immunology and neuroscience-oriented R&D capabilities. For biotech teams, the central outcome is access to linked omics at scale for retrospective and prospective study designs. Clinically, the agreement also reinforces the industry shift toward building “queryable” multi-omics real-world evidence pipelines to support mechanism work and trial planning.